This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novartis AG

Drug Names(s): PEG-musirudin, pegmusirudin

Description: SPP200 (pegmusirudin), a pegylated recombinant protein, is a long-acting direct thrombin inhibitor. SPP200 is designed to prevent clot formation in the graft used in hemodialysis. It has a duration of action of over 100 hours and is not removed from the patient's body during dialysis (unlike unfractionated heparin).

Deal Structure: Abbott acquired SPP200 through the acquisition of Knoll AG in 2002 before out-licensing it to Speedel in 2003. In August 2006, Abbott Laboratories decided not to exercise its license-back option for SPP200 and thereby granted all development, commercialization and marketing rights for SPP200 to Speedel.

In September 2008, Speedel was acquired by Novartis.

SPP200 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug